Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microba Life SciencesASX:MAP +12.50% 3-Year EBITDA Growth Rate is 18.20% as of Dec. 2025, which is at its 10-year median of 18.20. The stock has 6 warning signs investors should review. Among 164 Medical Diagnostics & Research companies, Microba Life Sciences ranks better than 61.59% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Microba Life Sciences was 18.20% per year. The lowest was 18.20% per year. And the median was 18.20% per year.
Microba Life Sciences (ASX:MAP) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Microba Life Sciences 3-Year EBITDA Growth Rate Related Terms
ASX:MAP vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's 3-Year EBITDA Growth Rate falls into.
Microba Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.20% mean?
Microba Life Sciences (ASX:MAP) has a 3-Year EBITDA Growth Rate of 18.20% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Microba Life Sciences and its competitors. This is near median its historical median of 18.20. Over the past decade, Microba Life Sciences' 3-Year EBITDA Growth Rate has ranged from 18.20 to 18.20. According to the industry distribution chart, Microba Life Sciences ranks #63 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 38.4%.
Is Microba Life Sciences' 3-Year EBITDA Growth Rate too high?
Microba Life Sciences' current 3-Year EBITDA Growth Rate of 18.20% is near median its 10-year median of 18.20. Over the past 10 years, this metric has ranged from a low of 18.20 to a high of 18.20. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.30. Microba Life Sciences' value of 18.20% is 61.1% above this industry median. Based on the distribution chart, Microba Life Sciences ranks #63 out of 164 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Microba Life Sciences' 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #63 out of 164 companies for 3-Year EBITDA Growth Rate. This puts Microba Life Sciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.30. Microba Life Sciences' value of 18.20% is 61.1% above this benchmark. Historically, Microba Life Sciences' own 3-Year EBITDA Growth Rate has ranged from 18.20 to 18.20 over the past decade. While the company's 10-year median is 18.20 vs. the industry median of 11.30, Microba Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.30, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microba Life Sciences's current 3-Year EBITDA Growth Rate of 18.20% is 61.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current 3-Year EBITDA Growth Rate is 18.20%, which is near median its own 10-year median of 18.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.24, compared to a current price of A$0.05 — trading 77.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 18.20%, which is near median its 10-year median of 18.20 and 61.1% above the Medical Diagnostics & Research industry median of 11.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current 3-Year EBITDA Growth Rate is 18.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 
